Literature DB >> 10705260

Co-expression of vascular endothelial growth factor and its receptor flt-1 in malignant pleural mesothelioma.

J König1, E Tolnay, T Wiethege, K Müller.   

Abstract

BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent angiogenic protein with a selective mitogenic effect on endothelial cells known to be involved in many normal and pathological processes. Coexpression of VEGF and its receptor flt-1 has been reported in different types of malignant tumors.
OBJECTIVE: In the present study we investigated the expression of VEGF and flt-1 in 90 cases of diffuse malignant pleural mesotheliomas.
METHODS: VEGF and flt-1 expression was analyzed by immunohistochemistry and non-radioactive in situ hybridization.
RESULTS: VEGF expression was visualized immunohistochemically in tumor cells. flt-1 expression correlated with histological differentiation (p < 0.013). Furthermore, expression of flt-1 was detected in tumor cells, macrophages and microvessels adjacent to tumor cells. VEGF and flt-1 expression were confirmed by in situ hybridization.
CONCLUSION: There was a statistically significant correlation between VEGF and flt-1 expression (p < 0.001). The observed coexpression of VEGF and flt-1 possibly suggests a potential autocrine loop for malignant pleural mesothelioma cells. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10705260     DOI: 10.1159/000029460

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  8 in total

1.  Mesothelioma: a review.

Authors:  Frank E Mott
Journal:  Ochsner J       Date:  2012

2.  Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.

Authors:  Linda L Garland; Kari Chansky; Antoinette J Wozniak; Anne S Tsao; Shirish M Gadgeel; Claire F Verschraegen; Marco A Dasilva; Mary Redman; David R Gandara
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

3.  Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions.

Authors:  Eva Ruiz; Carmen Alemán; José Alegre; Jasone Monasterio; Rosa Ma Segura; Lluis Armadans; Ana Vázquez; Teresa Soriano; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2005 May-Jun       Impact factor: 2.584

Review 4.  Peritoneal mesothelioma.

Authors:  R N Taub; M L Keohan; J C Chabot; K S Fountain; M Plitsas
Journal:  Curr Treat Options Oncol       Date:  2000-10

Review 5.  Novel and Promising Systemic Treatment Approaches in Mesothelioma.

Authors:  Elizabeth Dudnik; Daniel Reinhorn; Liran Holtzman
Journal:  Curr Treat Options Oncol       Date:  2021-08-23

6.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30

7.  Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma.

Authors:  Akiko Harada; Junji Uchino; Taishi Harada; Noriaki Nakagaki; Junko Hisasue; Masaki Fujita; Koichi Takayama
Journal:  Cancer Sci       Date:  2016-12-01       Impact factor: 6.716

8.  Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.

Authors:  Timothy R Holzer; Angie D Fulford; Drew M Nedderman; Tara S Umberger; Rebecca R Hozak; Adarsh Joshi; Symantha A Melemed; Laura E Benjamin; Gregory D Plowman; Andrew E Schade; Bradley L Ackermann; Robert J Konrad; Aejaz Nasir
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.